

Eculizumab 300mg concentrate for solution for infusion (Soliris®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2456	Treatment of adults with neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease.	Not routinely available as not recommended for use in NHS Scotland	19/01/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/eculizumab-soliris-non-sub-smc2456/>

Other Decision Specified

Date of ADTC 19/01/2022

Opicapone 50mg hard capsules (Ongentys®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2430	As adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	30/04/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/opicapone-ongentys-abb-smc2430/>

Other Decision Specified

Date of ADTC 19/01/2022

Budesonide 9mg prolonged release tablet (Cortiment®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2448	Induction of remission in patients with active microscopic colitis.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	30/04/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/budesonide-cortiment-abb-smc2448/>

Other Decision Specified

Date of ADTC 19/01/2022

Osimertinib 40mg and 80mg film-coated tablet (Tagrisso®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2382	As monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.	Available in line with local or regional guidance	16/02/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/osimertinib-tagrisso-resub-smc2382/>

Other Decision Specified

Date of ADTC 19/01/2022

Tralokinumab 150mg solution for injection in prefilled syringe (Adtralza®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2403	Treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. SMC restriction: patients who have had an inadequate response to an existing systemic immunosuppressant such as ciclosporin, or in whom such treatment is considered unsuitable.	Available in line with local or regional guidance	16/03/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/tralokinumab-adtralza-full-smc2403/>

Other Decision Specified

Date of ADTC 19/01/2022

Trastuzumab deruxtecan 100mg powder for concentrate for solution for infusion (Enhertu®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2388	As monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received two or more prior anti-HER2-based regimens.	Available in line with local or regional guidance	16/03/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/trastuzumab-deruxtecan-enhertu-full-smc2388/>

Other Decision Specified

Date of ADTC 19/01/2022

Tucatinib 50mg and 150mg film-coated tablets (Tukysa®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2398	In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.	Available in line with local or regional guidance	16/03/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/tucatinib-tukysa-full-smc2398/>

Other Decision Specified

Date of ADTC 19/01/2022

Nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2397	In combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.	Not routinely available as not recommended for use in NHS Scotland	19/01/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/nivolumab-opdivo-full-smc2397/>

Other Decision Specified

Date of ADTC 19/01/2022
